HVIVO PLC Logo

HVIVO PLC

HVO | IL

Overview

Corporate Details

ISIN(s):
GB00B9275X97
LEI:
213800VT5KBM7JLIV118
Country:
United Kingdom
Address:
QUEEN MARY BIOENTERPRISES INNOVATION CENTRE, E1 2AX LONDON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

hVIVO PLC is a specialist contract research organization (CRO) and a world leader in human challenge clinical trials for testing infectious and respiratory disease vaccines and therapeutics. The company provides end-to-end services, designing and conducting trials where volunteers are safely exposed to a pathogen to accelerate the evaluation of new medical interventions. Its expertise covers a wide range of well-established challenge models for diseases such as Influenza, RSV, COVID-19, hMPV, and Malaria. Leveraging state-of-the-art quarantine facilities, proprietary viral challenge agents, and comprehensive laboratory services, hVIVO supports a global client base of pharmaceutical and biotechnology companies in fast-tracking the development of their products.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for HVIVO PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-29 08:00
Board/Management Information
Proposed appointment of Chair
English 16.3 KB
2025-07-22 08:00
Earnings Release
H1 Trading update
English 26.7 KB
2025-07-18 08:00
Board/Management Information
Directorate Change
English 16.4 KB
2025-07-09 08:00
Report Publication Announcement
Notice of Trading Update
English 17.4 KB
2025-07-01 17:04
Major Shareholding Notification
Holding(s) in Company
English 24.3 KB
2025-06-30 08:00
Earnings Release
Positive results from client Phase 2b field study
English 22.0 KB
2025-06-05 14:00
Post-Annual General Meeting Information
Result of AGM
English 15.3 KB
2025-06-02 08:00
Director's Dealing
Director/PDMR Shareholding
English 48.9 KB
2025-05-30 08:00
Business and Financial Review
Trading update
English 18.7 KB
2025-05-29 08:00
Board/Management Information
Appointment of Independent Non-Executive Director
English 22.6 KB
2025-03-26 14:51
Board/Management Information
AIM Rule 17 and Schedule 2(g) Update
English 15.3 KB
2025-03-07 08:00
Director's Dealing
Director/PDMR Shareholding
English 40.4 KB
2025-02-27 08:00
M&A Activity
Acquisition of Cryostore for up to £3.2m
English 22.4 KB
2025-02-17 08:00
Earnings Release
£2m hMPV characterisation study contract
English 19.3 KB
2025-02-05 08:00
Legal Proceedings Report
Shionogi reports positive RSV trial results
English 19.3 KB

Automate Your Workflow. Get a real-time feed of all HVIVO PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for HVIVO PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Purple Biotech Ltd. Logo
Develops first-in-class cancer therapies targeting tumor immune evasion and drug resistance.
Israel PPBT
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC Logo
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom QBT
Quantum Genomics Logo
Develops digital twin solutions to simulate drug effects and personalize treatments.
France ALQGC
QUIA PHARMA AB Logo
Develops enhanced drugs using a patented, releasable pegylation drug delivery platform.
Sweden QUIA
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
Respiratorius AB Logo
Developing innovative drug candidates to enhance standard therapies for aggressive cancers.
Sweden RESP
ROQUEFORT THERAPEUTICS PLC Logo
Developing novel immuno-oncology medicines for hard-to-treat, resistant cancers.
United Kingdom ROQ
United States of America N/A